News
Heat exposure linked to developmental delays in early childhood, multinational study finds
1+ day, 11+ hour ago (273+ words) "We used linear probability models with geographic and seasonality fixed effects to account for baseline climatic conditions, as well as other individual and contextual covariates to address potential selection bias," wrote the investigators. Results showed that children exposed to average…...
David Fleischer, MD, discusses recent data for Viaskin Peanut patch
1+ day, 13+ hour ago (494+ words) David Fleischer, MD, says phase 3 VITESSE results show the Viaskin peanut patch offers a safe, practical desensitization option for young children with peanut allergy. New insights from the pivotal phase 3 VITESSE trial continue to shape the clinical conversation around epicutaneous…...
Why age matters for allergy success with David Fleischer, MD
1+ day, 16+ hour ago (11+ words) Why age matters for allergy success with David Fleischer, MD'Contemporary Pediatrics...
FDA accepts Tzield sBLA for stage 2 type 1 diabetes in children as young as 1 year
2+ day, 18+ hour ago (395+ words) With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication. The sBLA is supported by positive interim 1-year data from the ongoing PETITE-T1D (NCT05757713) phase 4 study, which is evaluating…...
Using genome sequencing as a proactive testing option
1+ week, 5+ day ago (58+ words) Using genome sequencing as a proactive testing option'Contemporary Pediatrics Trending on Contemporary Pediatrics Weekly review: Type 1 diabetes special report, FDA approvals, and more Mimi C. Lee, MD, PhD, discusses the evolving role of genomic testing in children Daniela Carvalho, MD, highlights…...
Phase 3 trial meets primary end point for Viaskin peanut patch in children aged 4 to 7 years
3+ week, 13+ hour ago (553+ words) Phase 3 data show the Viaskin peanut patch improved desensitization vs placebo in children aged 4 to 7 years, supporting a planned FDA BLA in 2026. The trial's primary end point was defined as the difference in responder rates between treatment groups after 12 months…...
Dale Lee, MD, explains best practices for celiac disease follow-up | Contemporary Pediatrics
1+ mon, 3+ week ago (341+ words) In this Contemporary Pediatrics video interview, Dale Lee, MD, highlights how pediatricians can be involved in celiac disease follow-up care. Lee outlined his recommendations for follow-up intervals, beginning shortly after diagnosis and initiation of a gluten-free diet. Lee highlighted that…...
Improved Pediatric AD Clinical Trial Design and Efficacy Outcomes | Contemporary Pediatrics
1+ mon, 3+ week ago (114+ words) Panelists discuss how improved clinical trial design helps ensure new treatments reflect real-world experiences and family priorities. Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates. Anil K. Agarwal,…...
FDA approves pediatric indication for SONU wearable device to treat nasal congestion
7+ mon, 3+ day ago (624+ words) The AI-enabled, wearable device is the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up. FDA approves pediatric indication for SONU wearable device to treat nasal congestion | Image credit: Contemporary Pediatrics The FDA has approved…...
Climate change: Challenges faced by the pediatric population
8+ mon, 3+ week ago (340+ words) The World Bank Group reports that as this global health emergency escalates, devastating impacts on health and well-being will also accelerate. This article aims to explore the multiple health effects of climate change on the pediatric population and the approaches…...